<?xml version="1.0" encoding="UTF-8"?>
<p>On account of their superior anti-mycobacterial activity, compounds 
 <bold>5g</bold> and 
 <bold>5h</bold> were selected for further 
 <italic>in silico</italic> investigation to explore their possible molecular target. Two promising drug enzymes in 
 <italic>M. tuberculosis</italic> were suggested as potential targets for the target compounds in this study; the flavoenzyme Decaprenylphosphoryl-
 <italic>β</italic>-D-Ribose 2′-Epimerase (DprE1) and the enoyl-acyl carrier protein reductase (InhA) enzymes. Both enzymes play an essential role in the metabolism of the cell wall and the synthesis of mycolic acid, respectively
 <xref rid="CIT0030" ref-type="bibr">
  <sup>30</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0031" ref-type="bibr">
  <sup>31</sup>
 </xref>. The selection of these two enzymes is based on a pilot docking study that explored the plausible binding interactions and energy scores for the prepared compounds with different enzyme targets.
</p>
